A detailed history of Vermillion Wealth Management, Inc. transactions in I Mab stock. As of the latest transaction made, Vermillion Wealth Management, Inc. holds 200 shares of IMAB stock, worth $194. This represents 0.0% of its overall portfolio holdings.

Number of Shares
200
Holding current value
$194
% of portfolio
0.0%

Shares

1 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2024

Feb 21, 2025

BUY
$0.85 - $1.6 $170 - $320
200 New
200 $170,000

Others Institutions Holding IMAB

About I-Mab


  • Ticker IMAB
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 83,098,800
  • Market Cap $80.6M
  • Description
  • I-Mab, a clinical stage biopharmaceutical company, discovers, develops, and commercializes biologics to treat cancer and autoimmune disorders. It is developing Felzartamab, a CD38 antibody that is in Phase 1b/2a for patients with membranous nephropathy; Eftansomatropin alfa, a long-acting human growth hormone, which has completed Phase 3 clinica...
More about IMAB
Track This Portfolio

Track Vermillion Wealth Management, Inc. Portfolio

Follow Vermillion Wealth Management, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vermillion Wealth Management, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Vermillion Wealth Management, Inc. with notifications on news.